Adverse Events After Receipt of an Inactive Coronavirus Disease-19 Vaccine  in Healthcare Professionals: A Cross-Sectional Study

Tansel Bekiroğlu Ergün; Yusuf Ergün

Makale detayları

Adverse Events After Receipt of an Inactive Coronavirus Disease-19 Vaccine in Healthcare Professionals: A Cross-Sectional Study

Yazarlar:

Tansel Bekiroğlu Ergün | Yusuf Ergün

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.15-21

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001285367

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objective: The vaccine manufactured by Sinovac has been licensed according to the emergency use authorization program in Turkey. Inherently, this product has many shortcomings regarding safety issues. The aim was to explore the potential adverse reactions of the vaccine. Materials and Methods: A retrospective cross-sectional study via a 24-item self-administered questionnaire was conducted among healthcare professionals. Results: Of 133 persons, 51 subjects 38 experienced adverse events after the first dose of the vaccine. The most common adverse events were fatigue, headache, diarrhea, and fever. Ninety five percent of the subjects n126 had the second dose of the vaccine and only 43 subjects 26 described adverse events. These events were similar to those seen after the first dose. In one person, acute hypertension elevation was considered to be a serious adverse event. A female dominance regarding the frequency of adverse events was, solely, detected after the first dose administration. Conclusion: Although there is a significant amount of adverse events in response to the vaccine, these cannot be identified as serious events. Therefore, this vaccine seems to be safe enough for those under the threat of the coronavirus disease 2019.

 Objective: The vaccine manufactured by Sinovac has been licensed according to the emergency use authorization program in Turkey. Inherently, this product has many shortcomings regarding safety issues. The aim was to explore the potential adverse reactions of the vaccine. Materials and Methods: A retrospective cross-sectional study via a 24-item self-administered questionnaire was conducted among healthcare professionals. Results: Of 133 persons, 51 subjects 38 experienced adverse events after the first dose of the vaccine. The most common adverse events were fatigue, headache, diarrhea, and fever. Ninety five percent of the subjects n126 had the second dose of the vaccine and only 43 subjects 26 described adverse events. These events were similar to those seen after the first dose. In one person, acute hypertension elevation was considered to be a serious adverse event. A female dominance regarding the frequency of adverse events was, solely, detected after the first dose administration. Conclusion: Although there is a significant amount of adverse events in response to the vaccine, these cannot be identified as serious events. Therefore, this vaccine seems to be safe enough for those under the threat of the coronavirus disease 2019.

 Objective: The vaccine manufactured by Sinovac has been licensed according to the emergency use authorization program in Turkey. Inherently, this product has many shortcomings regarding safety issues. The aim was to explore the potential adverse reactions of the vaccine. Materials and Methods: A retrospective cross-sectional study via a 24-item self-administered questionnaire was conducted among healthcare professionals. Results: Of 133 persons, 51 subjects 38 experienced adverse events after the first dose of the vaccine. The most common adverse events were fatigue, headache, diarrhea, and fever. Ninety five percent of the subjects n126 had the second dose of the vaccine and only 43 subjects 26 described adverse events. These events were similar to those seen after the first dose. In one person, acute hypertension elevation was considered to be a serious adverse event. A female dominance regarding the frequency of adverse events was, solely, detected after the first dose administration. Conclusion: Although there is a significant amount of adverse events in response to the vaccine, these cannot be identified as serious events. Therefore, this vaccine seems to be safe enough for those under the threat of the coronavirus disease 2019.

 Amaç: Sinovac tarafından üretilen aşı Türkiyede acil kullanım onayı programına göre ruhsatlandırılmıştır. Doğal olarak bu ürünün güvenlik sorunlarıyla ilgili birçok eksikliği vardır. Amaç aşının potansiyel yan etkilerini araştırmaktı. Gereç ve Yöntemler: Kendi kendine uygulanan 24 maddelik bir anket aracılığıyla sağlık çalışanları üzerinde retrospektif kesitsel bir çalışma yapıldı. Bulgular: Yüz otuz üç kişiden 51i 38 aşının ilk dozundan sonra yan etkiler yaşadı. En yaygın yan etkiler yorgunluk, baş ağrısı, ishal ve ateşti. Deneklerin yüzde doksan beşi n126 ikinci aşı dozunu aldı ve sadece 43 denek 26 advers olaylar tanımladı. Bu olaylar, ilk dozdan sonra görülenlere benzerdi. Bir kişide, akut hipertansiyon yükselmesi ciddi bir yan etki olarak kabul edildi. Yan etkilerin sıklığına ilişkin bir kadın baskınlığı, yalnızca ilk doz uygulamasından sonra tespit edildi. Sonuç: Aşıya yanıt olarak önemli miktarda yan etki olmasına rağmen, bunlar ciddi olaylar olarak tanımlanamaz. Bu nedenle, bu aşı 2019 koronavirüs hastalığı tehdidi altındakiler için yeterince güvenli görünüyor.

Makale detayları

Adverse Events After Receipt of an Inactive Coronavirus Disease-19 Vaccine in Healthcare Professionals: A Cross-Sectional Study

Yazarlar:

Tansel Bekiroğlu Ergün | Yusuf Ergün

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.15-21

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001285367

pISSN:

1303-6610

adverse drug event

COVID-19 vaccine

SARS-Cov-2 virus

safety

advers ilaç olayı

COVID-19 aşısı

SARS-COv-2 virüsü

güvenlilik

Sayı

Makale detayları

Yazarlar: Tansel Bekiroğlu Ergün | Yusuf Ergün

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.15-21

Belge Tipi: Makale

Yayın Tarihi: 3/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001285367

pISSN: 1303-6610

Sayı

Yazarlar:

Tansel Bekiroğlu Ergün | Yusuf Ergün

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.15-21

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001285367

pISSN:

1303-6610